Want to see CLNN full AI Analyst Report?
CLNN Stock Chart & Stats
$6.31
-$0.20(-3.40%)
At close: 4:00 PM EST
$6.31
-$0.20(-3.40%)
Day’s Range― - ―
52-Week Range$3.25 - $13.50
Previous CloseN/A
Volume48.08K
Average Volume (3M)78.64K
Market Cap
$75.65M
Enterprise Value$73.51
Total Cash (Recent Filing)$5.94M
Total Debt (Recent Filing)$22.05M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Aug 17, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.25
Shares Outstanding12,778,307
10 Day Avg. Volume61,738
30 Day Avg. Volume78,635
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-3.29
Price to Sales (P/S)289.36
P/FCF Ratio-3.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.20Price Target Upside410.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.69
Revenue Forecast (FY)$172.83K
Bulls Say, Bears Say
Bulls Say
Regulatory Progress Toward Accelerated ApprovalFDA feedback that CNM-Au8 data may support an accelerated NDA using neurofilament light as a surrogate materially shortens potential time to market if accepted. This de-risks the development pathway, improves partner and investor interest, and supports medium-term financing and commercialization planning.
Debt Maturity Extensions Reduce Near-term Cash OutflowsMultiple note amendments that defer monthly payments and extend maturities to August 2027 materially lower immediate cash demands. This gives management runway to prepare an NDA and plan a Phase 3 without near-term debt service, improving liquidity flexibility over the next several quarters.
Equity Financing Strengthens Cash RunwayThe $7M registered direct offering provides non-debt capital designated for NDA filing, manufacturing scale-up, and trial planning. This financing reduces immediate solvency pressure, supports program continuity, and lessens near-term reliance on additional secured borrowing or dilutive short-term financings.
Bears Say
Persistent Cash Burn And Operating LossesSustained negative operating and free cash flow (~-$18.1M TTM) and multi-year net losses indicate persistent cash consumption. With minimal revenue, the company will need ongoing external funding to sustain trials and operations, increasing dilution or creditor dependence and constraining strategic optionality.
Negative Equity And Elevated LeverageNegative shareholders' equity alongside ~$22M of debt signals weakened balance-sheet resilience. This elevated leverage reduces borrowing capacity, increases sensitivity to funding shortfalls, and heightens solvency risk if milestone or financing plans are delayed, constraining long-term financial flexibility.
High Clinical And Regulatory Execution RiskRelying on a biomarker surrogate and a required confirmatory Phase 3 in 2027 makes approval outcomes binary. Even with accelerated review potential, the company’s commercialization timing and revenue hinge on clinical validation and FDA acceptance, exposing the enterprise to significant program execution risk.
Clene News
CLNN FAQ
What was Clene Inc’s price range in the past 12 months?
Clene Inc lowest stock price was $3.25 and its highest was $13.50 in the past 12 months.
What is Clene Inc’s market cap?
Clene Inc’s market cap is $75.65M.
When is Clene Inc’s upcoming earnings report date?
Clene Inc’s upcoming earnings report date is Aug 17, 2026 which is in 27 days.
How were Clene Inc’s earnings last quarter?
Clene Inc released its earnings results on May 14, 2026. The company reported -$0.69 earnings per share for the quarter, missing the consensus estimate of -$0.637 by -$0.053.
Is Clene Inc overvalued?
According to Wall Street analysts Clene Inc’s price is currently Undervalued.
Does Clene Inc pay dividends?
Clene Inc does not currently pay dividends.
What is Clene Inc’s EPS estimate?
Clene Inc’s EPS estimate is -0.37.
How many shares outstanding does Clene Inc have?
Clene Inc has 12,778,307 shares outstanding.
What happened to Clene Inc’s price movement after its last earnings report?
Clene Inc reported an EPS of -$0.69 in its last earnings report, missing expectations of -$0.637. Following the earnings report the stock price went up 8.462%.
Which hedge fund is a major shareholder of Clene Inc?
Currently, no hedge funds are holding shares in CLNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.20 (410.30% Upside)
$32.20 (410.30% Upside)
Blogger Sentiment
Bullish
CLNN Sentiment 70%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 50.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
51.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-14.41%
Trailing 12-Months
Company Description
Clene Inc
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.
CLNN Stock 12 Month Forecast
Average Price Target
$32.20
▲(410.30% Upside)
Technical Analysis
Dyadic International
―
Akari Therapeutics
―
Estrella Immunopharma
―
AN2 Therapeutics, Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
37.89% Insiders
2.96% Mutual Funds
0.09% Other Institutional Investors
56.27% Public Companies and
Individual Investors